Panel submits operational evaluation of FDA’s tobacco program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Independent Expert Panel for Tobacco submitted its recommendations to Commissioner Robert Califf at FDA. The Operational Evaluation of FDA’s Tobacco Program was facilitated by the Reagan-Udall Foundation at the Commissioner’s request.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

FDA granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login